The study aims to investigate patient satisfaction in RMS and PPMS patients for whom
it has previously been decided that they will be treated with ocrelizumab s.c. as part of
their therapy.
Further aims include assessing the impact of ocrelizumab s.c. on change in NfL and
glial fibrillary acidic protein (GFAP) levels measured in serum and to evaluate the
practicability of measuring NfL in future clinical practice using the Elecsys research use
only (RUO) assay. This study will observe RMS and PPMS patients during routine
clinical practice treated with ocrelizumab s.c. for the first time.